Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Market Cap & Net Worth: Nykode Therapeutics AS (VACBF)
Nykode Therapeutics AS (PINK:VACBF) has a market capitalization of $70.86 Million ($70.86 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #22897 globally and #8047 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nykode Therapeutics AS's stock price $0.22 by its total outstanding shares 326546444 (326.55 Million).
Nykode Therapeutics AS Market Cap History: 2023 to 2025
Nykode Therapeutics AS's market capitalization history from 2023 to 2025. Data shows change from $515.94 Million to $70.86 Million (-68.28% CAGR).
Nykode Therapeutics AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nykode Therapeutics AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.06x
Nykode Therapeutics AS's market cap is 9.06 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $515.94 Million | $12.90 Million | -$35.15 Million | 39.99x | N/A |
| 2024 | $78.63 Million | $8.68 Million | -$38.82 Million | 9.06x | N/A |
Competitor Companies of VACBF by Market Capitalization
Companies near Nykode Therapeutics AS in the global market cap rankings as of March 19, 2026.
Key companies related to Nykode Therapeutics AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Nykode Therapeutics AS Historical Marketcap From 2023 to 2025
Between 2023 and today, Nykode Therapeutics AS's market cap moved from $515.94 Million to $ 70.86 Million, with a yearly change of -68.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $70.86 Million | -9.88% |
| 2024 | $78.63 Million | -84.76% |
| 2023 | $515.94 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Nykode Therapeutics AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $70.86 Million USD |
| MoneyControl | $70.86 Million USD |
| MarketWatch | $70.86 Million USD |
| marketcap.company | $70.86 Million USD |
| Reuters | $70.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.